Mathematical modelling, data science and biostatistics company Physiomics plc (AIM: PYC) announced on Wednesday that it has been awarded a new contract by long-standing client Numab Therapeutics AG, extending the application of its modelling expertise across Numab Therapeutics' development pipeline.

Under the agreement, Physiomics plc will develop a pharmacokinetic-pharmacodynamic model to inform the Target Candidate Profile of a key asset within Numab Therapeutics' immunology and inflammation pipeline. The project is designed to support early-stage, data-driven decision-making and is expected to commence imminently, with completion anticipated in Q2 2026.

The contract builds on an established relationship and supports Numab Therapeutics AG's focus on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology, while reinforcing Physiomics plc's role in accelerating therapeutic development through advanced modelling and data science.